Trial Profile
A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2017
Price :
$35
*
At a glance
- Drugs Hetrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 28 Nov 2015 New trial record